Unilever Plc
$192.76B- Market cap
- $140.06B
- Debt
- +$49.28B
- Cash
- −$3.94B
Capital structure 74% equity / 26% debt · EV / Revenue 3.28x · EV / EBITDA 16.57x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2023 ·
Decision snapshot: UL stock price at discount vs RVMD $64.22 current versus $104.49K implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at RVMD's multiple
Implied fair value · at UL's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: UL FY 2025 (ended Dec 31, 2025) · RVMD FY 2023 (ended Dec 31, 2023). Fiscal years are not aligned.
Trendline
Seven fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 74% equity / 26% debt · EV / Revenue 3.28x · EV / EBITDA 16.57x
Capital structure 100% equity / 0% debt · EV / Revenue 3744.77x
UL carries the larger enterprise value at $192.76B against $43.36B; UL trades on the lower EV / Revenue multiple (3.28x vs 3744.77x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
UNILEVER PLC · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Revolution Medicines, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
—
0.11x
Net debt / EBITDA
Leverage against operating earnings
4.53x
3.85x
Cash and equivalents
Liquid reserves on the balance sheet
$3.94B
$1.85B
Total debt
Interest-bearing obligations outstanding
$49.28B
$193.93M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PROCTER & GAMBLE Co
UL vs PG
COLGATE PALMOLIVE CO
UL vs CL
JOHNSON & JOHNSON
UL vs JNJ
KIMBERLY CLARK CORP
UL vs KMB
CHURCH & DWIGHT CO INC /DE/
UL vs CHD
AMGEN INC
UL vs AMGN
BRISTOL MYERS SQUIBB CO
UL vs BMY
GILEAD SCIENCES, INC.
UL vs GILD
INCYTE CORP
UL vs INCY
VERTEX PHARMACEUTICALS INC / MA
UL vs VRTX
Moderna, Inc.
UL vs MRNA
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.